Skeletal muscle depletion predicts the prognosis of patients with advanced pancreatic cancer undergoing palliative chemotherapy, independent of body mass index

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Choi, Younak ^a   Oh, Do Youn ^a   Kim, Tae Yong ^a   Lee, Kyung Hun ^b   Han, Sae Won ^b   Im, Seock Ah ^c   Kim, Tae You ^c   Bang, Yung Jue ^c  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Dongguk University Gyeongju Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; BODY COMPOSITION; BODY HEIGHT; BODY MASS; BODY WEIGHT; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL SYSTEM PARAMETERS; OVERALL SURVIVAL; PANCREAS CANCER; PREVALENCE; RETROSPECTIVE STUDY; SARCOPENIA; SEX DIFFERENCE; SKELETAL MUSCLE; TREATMENT OUTCOME; TREATMENT RESPONSE; VERY ELDERLY; DIAGNOSTIC IMAGING; MIDDLE AGED; MORTALITY; MUSCLE ATROPHY; PALLIATIVE THERAPY; PANCREATIC NEOPLASMS; PATHOLOGY; PROGNOSIS; RADIOGRAPHY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BODY COMPOSITION; BODY MASS INDEX; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; MUSCULAR ATROPHY; PALLIATIVE CARE; PANCREATIC NEOPLASMS; PROGNOSIS; RADIOGRAPHY; RETROSPECTIVE STUDIES; SARCOPENIA; YOUNG ADULT;

EID: 84947212795     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0139749     Document Type: Article

References (28)

1. Andreyev HJ, Norman AR, Oates J, Cunningham D (1998) Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer 34:503-509.
2. Choi Y, Kim TY, Lee KH, Han SW, Oh DY, Im SA, et al. (2014) The impact of body mass index dynamics on survival of patients with advanced pancreatic cancer receiving chemotherapy. J Pain Symptom Manage 48:13-25. doi: 10.1016/j.jpainsymman.2013.08.017
3. Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE (2008) A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 33:997-1006. doi: 10.1139/H08-075
4. Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. (2008) Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 9:629-635. doi: 10.1016/S1470-2045(08) 70153-0
5. Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, et al. (2013) Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 31:1539-1547 doi: 10.1200/JCO.2012.45.2722
6. Tan BH, Birdsell LA, Martin L, Baracos VE, Fearon KC. (2009) Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res 15:6973-6979. doi: 10. 1158/1078-0432.CCR-09-1525
7. Veasey Rodrigues H, Baracos VE, Wheler JJ, Parsons HA, Hong DS, Naing A, et al. (2013) Body composition and survival in the early clinical trials setting. Eur J Cancer 49:3068-3075. doi: 10.1016/j.ejca. 2013.06.026
8. Lieffers JR, Bathe OF, Fassbender K, Winget M, Baracos VE. (2012) Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery. Br J Cancer 107:931-936. doi: 10.1038/bjc.2012.350
9. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12:489-495. doi: 10.1016/S1470-2045(10)70218-7
10. Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, et al. (1998) Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 147:755-763.
11. Wen X, Wang M, Jiang CM, Zhang YM. (2011) Are current definitions of sarcopenia applicable for older Chinese adults? J Nutr Health Aging. 15:847-851.
12. Mitsiopoulos N, Baumgartner RN, Heymsfield SB, Lyons W, Gallagher D, Ross R. (1998) Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol (1985) 85:115-122.
13. Biolo G, Zorat F, Antonione R, Ciocchi B. (2005) Muscle glutamine depletion in the intensive care unit. Int J Biochem Cell Biol 37:2169-2179.
14. Washington TA, White JP, Davis JM, Wilson LB, Lowe LL, Sato S, et al. (2011) Skeletal muscle mass recovery from atrophy in IL-6 knockout mice. Acta Physiol (Oxf). 202:657-669.
15. Biolo G, Cederholm T, Muscaritoli M. (2014) Muscle contractile and metabolic dysfunction is a common feature of sarcopenia of aging and chronic diseases: from sarcopenic obesity to cachexia. Clin Nutr 33:737-748. doi: 10.1016/j.clnu.2014.03.007
16. Muller MJ, Wang Z, Heymsfield SB, Schautz B, Bosy-Westphal A. (2013) Advances in the understanding of specific metabolic rates of major organs and tissues in humans. Curr Opin Clin Nutr Metab Care 16:501-508.
17. Olsen RH, Krogh-Madsen R, Thomsen C, Booth FW, Pedersen BK. (2008) Metabolic responses to reduced daily steps in healthy nonexercising men. JAMA 299:1261-1263. doi: 10.1001/jama.299.11. 1259
18. Demontis F, Piccirillo R, Goldberg AL, Perrimon N. (2013) The influence of skeletal muscle on systemic aging and lifespan. Aging Cell 12:943-949. doi: 10.1111/acel.12126
19. Aversa Z, Bonetto A, Penna F, Costelli P, Di Rienzo G, Lacitignola A, et al. (2012) Changes in myostatin signaling in non-weight-losing cancer patients. Ann Surg Oncol 19:1350-1356. doi: 10.1245/s10434-011-1720-5
20. Cosqueric G, Sebag A, Ducolombier C, Thomas C, Piette F, Weill-Engerer S. (2006) Sarcopenia is predictive of nosocomial infection in care of the elderly. Br J Nutr 96:895-901.
21. Kyle UG, Pirlich M, Lochs H, Schuetz T, Pichard C. (2005) Increased length of hospital stay in underweight and overweight patients at hospital admission: a controlled population study. Clin Nutr 24:133-142.
22. Huillard O, Mir O, Peyromaure M, Tlemsani C, Giroux J, Boudou-Rouquette P, et al. (2013) Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. Br J Cancer 108:1034-1041. doi: 10.1038/bjc.2013.58
23. Aslani A, Smith RC, Allen BJ, Pavlakis N, Levi JA (2000) The predictive value of body protein for chemotherapy-induced toxicity. Cancer 88:796-803.
24. Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, et al. (2009) Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 15:2920-2926. doi: 10.1158/1078-0432. CCR-08-2242
25. Antoun S, Baracos VE, Birdsell L, Escudier B, Sawyer MB (2010) Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol 21:1594-1598. doi: 10.1093/annonc/mdp605
26. Gallagher D, Visser M, De Meersman RE, Sepulveda D, Baumgartner RN, Pierson RN, et al. (1997) Appendicular skeletal muscle mass: effects of age, gender, and ethnicity. J Appl Physiol (1985) 83:229-239.
27. Lau EM, Lynn HS, Woo JW, Kwok TC, Melton LJ (2005) Prevalence of and risk factors for sarcopenia in elderly Chinese men and women. J Gerontol A Biol Sci Med Sci. 60:213-216.
28. Kim YS, Lee Y, Chung YS, Lee DJ, Joo NS, Hong D, et al. (2012) Prevalence of sarcopenia and sarcopenic obesity in the Korean population based on the Fourth Korean National Health and Nutritional Examination Surveys. J Gerontol A Biol Sci Med Sci 67:1107-0013. doi: 10.1093/gerona/gls071